A New Beginning for Cervical Cancer Treatment

For women with treatment-resistant, recurrent or metastatic cervical cancer, the new standard for first-line treatment in the PD-L1-positive patient group is the addition of pembrolizumab to chemotherapy with bevasizumab.
The KEYNOTE-826 study was presented at the European Society for Medical Oncology (ESMO) Congress 2021.
The Role of Immunotherapy in Cervical Cancer
This clinical trial showed that the addition of pembrolizumab, an immunotherapy in the checkpoint inhibitor class ( Keytruda ), to standard chemotherapy (with or without bevasizumab), compared with chemotherapy alone, reduced the risk of both disease progression and death by approximately one third.
The benefit of adding pembrolizumab was seen both in the overall study population and in patients with higher levels of programmed death ligand-1 (PD-L1) positivity, but not in those with PD-L1-negative tumors.
Overall, the data from KEYNOTE-826 suggest that pembrolizumab plus platinum-based chemotherapy, with or without bevasizumab, may be a new first-line standard of care. The study also appeared at the same time in The New England Journal of Medicine as an online publication.
Since 2014, for patients with recurrent, treatment-resistant or metastatic cervical cancer, standard treatment, based on the GOG 240 study results, has been platinum plus paklitaksel doublet chemotherapy plus bevasizumab.
Immunotherapy with PD-1 inhibitors shows efficacy as monotherapy in second-line or later treatment for women with cervical cancer (see the relevant FDA approval), but until now there had been no data on adding these agents to chemotherapy.
There is a strong rationale for using checkpoint inhibitors targeting PD-1 in patients with cervical cancer, because PD-L1 is a consistent biomarker for infection with human papillomavirus (HPV), which is responsible for cervical cancer.
PD-L1 is substantially positive in cervical cancer and can be detected by immunohistochemical staining. The PD-L1 molecule on the surface of cancer cells and some immune cells can bind to PD-1 on T cells and thereby inhibit their function, reducing the immune response. These findings show that targeting the PD-1/PD-L1 pathway could and should be therapeutically effective. PD-L1 should be considered in cervical cancer treatment.
Details of the KEYNOTE-826 Study
- KEYNOTE-826 was a double-blind trial conducted in 617 patients classified as metastatic at diagnosis.
- Patients' PD-L1 combined positive scores (CPS) were classified as follows:
- < 1,
- 1 to < 10 or
- ≥ 10.
- Patients were randomized 1:1 to pembrolizumab or placebo every 3 weeks for up to 35 cycles, plus platinum-based chemotherapy (with bevacizumab added at the investigator's discretion).
- Progression-free survival and overall survival were defined as the primary endpoints of the study.
Survival Results
- After a median follow-up of 22 months, the 12-month progression-free survival rate in all patients with PD-L1 CPS ≥ 1 was 45.5% in the pembrolizumab group and 34.1% in the placebo group.
- Pembrolizumab reduced the risk of cancer progression by 48% in the PD-L1-positive patient group.
- For the entire patient group, progression-free survival rates were 44.7% versus 33.5%.
- In patients with PD-L1 CPS ≥ 10, progression-free survival rates were 44.6% and 33.5%, respectively.

- In all patients with PD-L1 CPS ≥ 1, the 12-month and 24-month overall survival rates were 75.3% and 53%, respectively, for patients receiving pembrolizumab, versus 63.1% and 41.7% for patients receiving placebo. This shows that pembrlizumab reduced the risk of death by 36%.
- In the entire patient group, the 12- and 24-month overall survival rates were 74.8% and 50.4% with pembrolizumab, and 63.6% and 40.4% with placebo, respectively. This difference meant a 33% reduction in the risk of death for pembrolizumab.
- Among patients with higher PD-L1 levels (≥ CPS 10), the corresponding overall survival rates were 75.7% and 54.4% with pembrolizumab, versus 61.5% and 44.6% with placebo.
- However, in the PD-L1-negative subgroups, there was no significant improvement in survival data.
The most common grade ≥ 3 adverse events were anemia, occurring in 30.3% of patients receiving pembrolizumab and 26.9% in the placebo group, and neutropenia, occurring in 12.4% and 9.7% of patients, respectively. One patient in the pembrolizumab group died of encephalitis, an immune-related event.
In conclusion, adding pembrolizumab immunotherapy to first-line treatment for women with advanced cervical cancer whose tumors are PD-L1-positive leads to approximately a one-third reduction in the risk of death and establishes the new standard of treatment for this group of patients.
Sources
2. ESMO Congress 2021. Abstract LBA2. Presented September 18, 2021.
3. New Standard of Care in Cervical Cancer - Medscape - Sep 19, 2021.
Was this article helpful?
Your feedback helps us improve our content.





Reader comments
Share your comment
Your name and comment are published only after administrator approval. Your email address is never shown to visitors.
Be the first to comment.